Bard, Medtronic Get Additional CMS Reimbursement for Their Drug-Coated Balloons
Wednesday, June 10, 2015
Source: Fierce Medical Devices
C.R. Bard announced that the federal Centers for Medicare & Medicaid Services further improved reimbursement for its recently launched Lutonix drug-coated balloon for peripheral artery disease in the femoropopliteal arteries (located near the knee).
"After further review, CMS determined that costs associated with DCBs were not included in existing reimbursement for percutaneous transluminal angioplasty, stenting, or atherectomy procedures. Therefore, CMS is removing the device offset charge from the calculation and will reimburse the full cost of DCBs in these procedures. This reimbursement determination is retroactive to April 1, 2015," the company said in a release.